in a prospective multicenter study , 244 men with highly or moderately differentiated prostatic cancer in stage i , ii or iii ( vacurg ) were consecutively randomized to three groups of treatment : group a ( 77 patients ) received polyestradiol phosphate ( estradurin , leo ) 80 mg i.m . every fourth week + ethinyl estradiol ( etivex , leo ) 150 micrograms daily , group b ( 72 patients ) estramustine phosphate ( estracyt , leo ) 280 mg twice daily , and group c ( 76 patients ) no therapy .
C0071554
polyestradiol phosphate
C0687716
estradurin